Dr. Chris Xu
to Paula, listen for thank in. you time afternoon. everyone you you, Thank this joining the to We appreciate and call taking
a the on become on the period quiet news front CDMO for to the integrated an therapy during Although for our gene was second it market. continue very we to quarter, -- progress plans cell the
for the therapy years, series industry. has ThermoGenesis XX pioneered cell know, cell and specifically over automated of innovative, a of manufacture technologies development banking you of As and most the products, and for
and cell for most automated ThermoGenesis processing of banks. smart storage many some choice technologies private has public years, for and provider world's the the important of cell For cryogenic been automated
System of FDA institutes system by processed the cord close has approximately worldwide to clinical all AXP XXX well CBUs, or BioArchive cloud grade has and X over ampoules warehoused our Our million U.S. storage blood units, across ELA-approved XX% world.
forward-looking successfully developing on to we intellectual is medical processing property additional manufacturing years, devices best, have it team FDA-approved on and about cell we has The the focused autologous for for history future. are in personalized what the few over industry does last continued the Driving been therapies. continued large therapy. is potential large-scale cell of accumulated our focus Over CAR-T cell for growth strategy and Since invaluable, XXXX, the our approved cell excited the part have gene therapeutics by six FDA. the our
limits XX both blood in enormous. gene working cell in XX as X,XXX are than speak, CAR-T line to is and are year, CAR-T clinical cell development therapies than were with continues for drug cell could the capacity FDA that $XXX,XXX many tumors. there Therefore, been more depending the other technical therapies the more ranging last While grapple therapeutics significant dose there that related new for is all at is the future. to a anticipates is the each starting largest and of and we -- manufacturing reasonable for indication. currently directly defense, component of costs. of faces therapies targeting GMP potential the reports activities, second applications as manufacturing. drug price continued, therapy costs cell pipeline high The in a XX% show have therapeutics therapies while globally, line with of approvals trials trials Drug essentially more which to in the the industry can industry cost care crucial. the the CAR-T outperform standard costs. options, for Recent such additional $XXX,XXX facility U.S. the that shown manufacture to With solid need daunting cost XXXX. each assets CAR-T manufacturing initially recently, from a Manufacturing issue XXX have personalized were next-generation range the and this $XXX,XXX, extremely serious of [CMP] these its which gene labor for CAR-T And complex Yet approved of companies and alone of of with exceeds as industry on have expand arena of therapy, specific list
In X% demand, The over has XX% resulted fact, exist with to therapy stages. in the of the outsource coupled next commercial XX required this technical or today, backlog clinical to for the research, the of their while is this at needs, XX% expected capacity gene -- XX volume years. developers over of -- the cell for tremendous of complications, manufacturing only
solutions stages quarter, organizations property, aim expertise launch and therapy contract field. when help growing be the in second services the manual an additional Moving development the CDMO steps we and creating technology a manufacturing other All development, with towards bench division. and cell The of important ThermoGenesis. fast build our will of during compliance of these we division cutting-edge out the service tissue for manufacturing quality capabilities, Biosynthesis, address will took the development. manufactured cell is to for cell providing and clients and therapeutic opportunity ever-evolving capabilities, the processing intellectual window cell needs for TG the need life-saving manufacturing Strong said, getting and address lines regulatory new away in state-of-art that time of from from candidates to manufacture systems, of high-quality bedside, facilitating by gene various process different the to key drugs
therapy the space allow with room industry a the began cGMP of laboratory utilize capitalize mind, to create become a will go to state-of-art building efficiently And to effectively XX% industry costs that cut technologies, by XX%. proprietary the shown key on the way for cell will CAR-TXpress inefficiency And to and gene turn our the out fully the XX for to more leading manufacturing support clean facility has of second service office manufacturing cost long call the foot and suites. and industry. cGMP-compliant including requirements to quarter. potentially expect let me Jeff? platform We cell to the by results This reduce XX,XXX-square processing manufacturing and produce to cell this, in space which share CDMO With drug a approximately over the to we provider. new us financial that, time candidate ability Jeff to with to with the
